A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia

Autor: Ada M. Kruisbeek, Tanja D. de Gruijl, Malika Koppes, Jorn Kaspers, Sandra van Wetering, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Saskia J. A. M. Santegoets, Yvonne den Hartog, Corien Eeltink, Satwinder Kaur Singh

Publikováno v: Cancer Immunology, Immunotherapy
Cancer Immunology and Immunotherapy, 67(10), 1505-1518. Springer Science and Business Media Deutschland GmbH
van de Loosdrecht, A A, van Wetering, S, Santegoets, S J A M, Singh, S K, Eeltink, C M, den Hartog, Y, Koppes, M, Kaspers, J, Ossenkoppele, G J, Kruisbeek, A M & de Gruijl, T D 2018, ' A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia ', Cancer Immunology and Immunotherapy, vol. 67, no. 10, pp. 1505-1518 . https://doi.org/10.1007/s00262-018-2198-9
Cancer Immunology, Immunotherapy, 67(10), 1505-1518

In elderly acute myeloid leukemia (AML) patients post-remission treatment options are associated with high comorbidity rates and poor survival. Dendritic cell (DC)-based immunotherapy is a promising alternative treatment strategy. A novel allogeneic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef36f686f0fe8c6ea1435348e856c7c3
https://doi.org/10.1007/s00262-018-2198-9

Effects of Food on the Pharmacokinetics of Nilotinib in Chronic Myeloid Leukemia: Enabling Significant Dose Reduction and Relief of Treatment Burden: The NIFOStudy

Autor: Christel C. L. M. Boons, René M. Vos, Jacqueline G. Hugtenburg, Jeroen Janssen, Yvonne den Hartog, Eleonora L. Swart, N. Harry Hendrikse, Anthe S. Zandvliet

Publikováno v: Boons, C C, den Hartog, Y, Janssen, J J, Zandvliet, A S, Vos, R, Swart, E L, Hendrikse, N H & Hugtenburg, J G 2018, ' Effects of Food on the Pharmacokinetics of Nilotinib in Chronic Myeloid Leukemia: Enabling Significant Dose Reduction and Relief of Treatment Burden: The NIFOStudy ', Blood, vol. 132 . https://doi.org/10.1182/blood-2018-99-118149
Blood, 132. American Society of Hematology

Introduction The twice daily dosing of nilotinib in the absence of food is a considerable burden for patients with chronic myeloid leukemia (CML). In order to simplify the dosing regimen and reduce treatment costs while taking advantage of the food d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c92c81e340d36ec5e52c6ffccd736d4
https://research.vumc.nl/en/publications/ca196621-37a7-4f40-a66c-6eeba7330b3a